In-vivo analysis of neuroblastoma targeting potential of aGD2-SIRPα fusion antibodies for local CD47 blockade
Laboratory evidence shows a new antibody design can attack neuroblastoma cells while sparing healthy blood cells, promising safer immunotherapy options.
This preclinical study demonstrates that human aGD2-hSIRPα bispecific fusion antibodies can selectively target GD2+ neuroblastoma cells while avoiding the CD47 antigen sink problem that limits standalone anti-CD47 therapy. The C-terminal hSIRPα configuration showed effective tumor targeting with minimal red blood cell binding, supporting advancement toward clinical development for high-risk neuroblastoma.
What the study was
- Study design
- Preclinical in vivo study (syngeneic and xenograft mouse models)
- Population
- Murine neuroblastoma (9464D-Luc-GFP) and human neuroblastoma xenograft (SK-N-AS) models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Molecular Cancer Therapeutics
Why it surfaced
Novel bispecific antibody approach for pediatric neuroblastoma (rare disease, high unmet need) with proof-of-concept tumor-selective CD47 blockade; preclinical only, capped at 6.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.